CHILDREN’S HOSPITAL ROYAL OPENING FULLY EQUIPPED WITH COMPUMEDICS LATEST NEUROLOGY TECHNOLOGY
Compumedics Limited (ASX:CMP) is pleased to announce another significant milestone with the opening of the neurological laboratory at the Royal Children’s Hospital (RCH) in Melbourne as part of the official opening of the hospital by her Majesty Queen Elizabeth.
Compumedics Limited (ASX:CMP) is pleased to announce another significant milestone with the opening of the neurological laboratory at the Royal Children’s Hospital (RCH) in Melbourne as part of the official opening of the hospital by her Majesty Queen Elizabeth. The RCH’s pediatric epilepsy(EEG) facility will be the largest in the Southern Hemisphere. Compumedics has delivered its latest EEG technology, which will be used for routine clinical EEG and surgical monitoring. This purchase represents another major milestone in Compumedics’ entry into the global $250 million LTM/Neurophysiology market.
The sale, with an order value of more than $500K will be a significant reference site and catalyst for future sales in Australia and the Asia Pacific region, including China.
The RCH project is the largest hospital redevelopment in Victoria’s history, valued in excess of $1 billion The project comprises in-patient facilities, operating theatres, pathology laboratories and various specialised functions for state of the art clinical care; befitting the ambitions of a project which aims to sit at the forefront of healthcare facilities internationally.
Consequently Compumedics was selected to supply its latest EEG technology including the NEUVO® LTM EEG system, which can record 64 individual channels of high-density EEG data on a single patient for days or weeks at a time. The GraelHD system provides high definition EEG signals and the Siesta802 remains the industry’s most compact wireless EEG recording device. Compumedics’ digital amplifier technology and breadth of EEG diagnostic offerings is superior to all other existing competitors and provides Compumedics with a unique point of differentiation. Compumedics’ product offerings provide higher quality brain recordings and more precise brain analysis, improving patient outcomes.
The RCH Melbourne is one of the world’s best children’s hospitals. It is internationally recognised as a leading centre of paediatric treatment, teaching and research. The RCH is the major specialist paediatric hospital in Victoria and its care extends to children from Tasmania, southern New South Wales and other states around Australia and overseas.
The RCH Epilepsy Program states that “1 in 20 (5%) children will have a seizure of some form during childhood. About 1 in 200 (0.5%) children have epilepsy.”
In commenting on the RCH facility, Dr. David Burton, Chairman and Chief Executive Officer of Compumedics Group said,
“The completion of this contract is another important milestone for our Company. It reinforces our commitment to our customers and the patients under their care. The world-class Royal Children’s Hospital installation establishes a new and innovative standard for long term EEG monitoring. This project further underpins our strategy to grow our business across this important but relatively new market sector for Compumedics.”
Compumedics Limited, was founded in 1987 by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology.
In 1987 Compumedics established Asia Pacific’s first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices.
In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries.
In 1998 Compumedics was awarded the overall Australian Exporter of the Year.
In 2000 Compumedics was listed on the Australian Stock Exchange.
In 2002, Compumedics acquired US-based Neuroscan – the world’s leading supplier of instruments for brain research. In the US – the world’s largest medical device market – Neuroscan holds around 90% of the market for brain-research products.
In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy.
In 2004, Compumedics acquired Germany-basedDWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields.
In 2006, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product.
In 2007, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame.
In 2008 the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from $9 million (1999) to $39 million (2008).
In 2009 Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product.
In 2010 Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia’s Top 100 Health Innovators through its’ world leading devices for sleep diagnostics.
For further background please visit: www.compumedics.com
For further information please contact:
Dr David Burton
Executive Chairman, CEO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Investor Relations & Media Enquires:
Mr Rod North
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 (0) 408 670 706
Investors: CMP.ASX (ASX.COM)